Dong Song Wei
Unternehmenssekretär bei SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.
Vermögen: 30 049 $ am 30.04.2024
Profil
Dong Song Wei currently works at Sinopharm YiXin Pharmaceutical Co., Ltd., as Director and Shanghai Shyndec Pharmaceutical Co., Ltd., as Board Secretary & Vice President from 2012.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.04.2023 | 20 000 ( 0,00% ) | 30 049 $ | 30.04.2024 |
Aktive Positionen von Dong Song Wei
| Unternehmen | Position | Beginn |
|---|---|---|
| SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Unternehmenssekretär | 09.01.2012 |
Sinopharm YiXin Pharmaceutical Co., Ltd.
 Sinopharm YiXin Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Sinopharm Holding A-Think Pharmaceutical Co., Ltd. engages in the manufacture and sale of injection mannose peptide. Its products and services include Octreotide acetate injection, Adenosine monophosphate for injection, Leucovorin for injection, Ondansetron hydrochloride injection, Sodium norcantharidin for injection, Norcantharidin tablet, Total saponin of ginseng stem and leaf tablets, Ginseng stems and leaves total saponin capsules, Vinorelbine tartaric acid for injection, and Poly-long-acting anti-bacterial membrane liquid material. The company was founded on December 10, 1997 and is headquartered in Changchun, China. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Sinopharm YiXin Pharmaceutical Co., Ltd.
Sinopharm YiXin Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Sinopharm Holding A-Think Pharmaceutical Co., Ltd. engages in the manufacture and sale of injection mannose peptide. Its products and services include Octreotide acetate injection, Adenosine monophosphate for injection, Leucovorin for injection, Ondansetron hydrochloride injection, Sodium norcantharidin for injection, Norcantharidin tablet, Total saponin of ginseng stem and leaf tablets, Ginseng stems and leaves total saponin capsules, Vinorelbine tartaric acid for injection, and Poly-long-acting anti-bacterial membrane liquid material. The company was founded on December 10, 1997 and is headquartered in Changchun, China. | Health Technology |
